Lipum’s toxicology- and safety program of SOL-116 successfully completed
Press release: Umeå, 17 June 2022. Lipum (publ) reports that the GLP toxicology- and safety program on the candidate drug (SOL-116) has been completed. The drug antibody was well tolerated also in high doses and the results supports submission of a Clinical Trial Application (CTA).The non-clinical program for toxicology- and safety studies of Lipum’s candidate drug (SOL-116) has been carried out in collaboration with the contract research organisation (CRO) Charles River Laboratories. They have now released the final report of the last study of the program concluding the results from the 13-